The FMT era has been productive, but now it’s time to rally together as an industry to accelerate next-generation LBP drug discovery, development and FDA approval.
ImmunoPrecise Antibodies Ltd. , an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has successfully solved the Information Integration. | May 30, 2023
ImmunoPrecise Antibodies Ltd. an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company s Chief Executive Officer and President, will present. | May 17, 2023